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Introduction: Many hypertension international guidelines recommend
the use of ﬁxed-dose combination of antihypertensive therapies as a
ﬁrst- line in high-risk hypertensive patients, in whom more rapid and
pronounced blood pressure (BP) control is desired. The aim of this
study was to evaluate the eﬀectiveness, safety and tolerability of the
single-pill combination of amlodipine/valsartan among Egyptian
patients with arterial hypertension in a real-life setting.
Method: This prospective, open-label, multi-center, non-comparative
post-marketing surveillance study enrolled adults with arterial hyper-
tension (systolic BP >140 mmHg and/or diastolic BP >90 mmHg)
treated with single-pill combination (SPC) of amlodipine/valsartan;
5/160 mg or 10/160 mg once daily dose. Patients were observed over
a 3-months period with approximately monthly intervals between
clinic visits. Primary objectives were comparison of systolic and dia-
stolic blood pressure and heart rate at study start and after 12 weeks
of therapy. Secondary objectives were evaluation of the blood pressure
lowering eﬀect in terms of response rates, evaluation of safety and tol-
erability of study medication.
Results: A total of 2489 patients were enrolled and 2357 completed the
study. Mean age was 54 years and 85% of patients had received prior
antihypertensive therapy. At study end, a signiﬁcant mean BP reduc-
tion of 39.4/21.7 mmHg (baseline: 171.5/103.4 mmHg; p < 0.001)
was seen in the overall population. The corresponding mean BP reduc-
tion for patients on amlodipine/valsartan 5/160 mg was 34.6/
19.2 mmHg (baseline: 166/101 mmHg; p < 0.001) and for patients
on amlodipine/valsartan 10/160 mg was 47.1/24.3 mmHg (baseline:
178.6/106.4 mmHg; p < 0.001). In a post-hoc analysis for subgroups
with important co-morbid conditions, the corresponding mean BP
reductions were: patients with diabetes; 41.1/21.6 mmHg (baseline
173.2/103.5 mmHg; p= 0.00001), patients with history of heart fail-
ure; 45.2/22.8 mmHg (baseline 175.9/104.6 mmHg; p= 0.00001),
patients with history of coronary heart diseases; 43/22.7 mmHg
(baseline: 175.8/105 mmHg; p= 0.00001). A small change in the heart
rate was noticed (82 bpm at baseline and 78.4 bpm at the end of study;
p < 0.001). 70.3% of patients had their blood pressure controlled (BP
<140/90 mmHg). Subjective investigators assessment as “excellent to
very good” for amlodipine/valsartan SPC was 97.3% for eﬀectiveness
and 96.8% for tolerability. The corresponding investigators and
patients assessment for compliance was 96.6% and 93.3% respectively.
Adverse events were reported in 4.4% of patients mainly due to edema
in 3.6%. Amlodipine/valsartan SPC was generally well tolerated.
Conclusion: The Results of this study showed that Single-pill combina-
tion of amlodipine/valsartan eﬀectively reduced BP among Egyptian
hypertensive patients with high tolerability proﬁle and provided evi-
dence that most of hypertensive patients may beneﬁt from this combi-
nation.
Introduction: High blood pressure is the most common cause of death
estimated to aﬀect at least 25% of all adults. The risk of cardiovascular
disease doubles with every increase of 20/10 mmHg above a normal
blood pressure. Antihypertensive medications not only lower blood
pressure, but also reduce the risk of stroke or Cardiovascular diseases.
Despite the availability of a wide range of antihypertensive medica-
tions, about 70% of hypertensive patients fail to achieve a blood
pressure control target of less than 140/90 mmHg.1,2Data from diﬀer-
ent national and regional surveys show that hypertension is common in
developing countries, and the rates of awareness, treatment, and con-
trol are low. The increased prevalence in developing countries possibly
caused by urbanization, ageing of population, changes of dietary hab-
its, and social stress. Almost three-quarters of people with hyperten-
sion (639 million people) live in developing countries with limited
health resources and where people have a very low awareness of hyper-
tension and poor blood pressure control.3
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In Egypt, Patients aware of their disease accounts only for 37.5%
of which 23.9% are treated and 8% only are controlled.3
The guidelines acknowledge that most patients with hypertension
require 2 or more antihypertensive medications to achieve blood pres-
sure control. Accordingly, initiation of therapy with 2 drugs is recom-
mended in patients whose blood pressure is more than 20/10 mmHg
above goal, either as separate agents or in a ﬁxed-dose combination.
One of the combinations recommended by the ESH/ESC guidelines
is the combination of a calcium channel blocker with an angiotensin
receptor blocker.2
Fixed dose combination of Valsartan plus Amlodipine is an eﬀec-
tive and well tolerated antihypertensive medication. Data showed that
the two complementary mechanisms of action of calcium channel
blocker and angiotensin receptor blocker helped more patients to reach
their recommended blood pressure goals.4
Furthermore, a recent study conducted on 8336 patients to evalu-
ate the eﬀectiveness and safety of amlodipine/valsartan single pill com-
bination (SPC) showed that an optimal blood pressure (BP) reduction
was achieved for all hypertension grades, including patients with iso-
lated systolic hypertension. The treatment was well tolerated with
few adverse events (AEs).5
Due to the fact of limited available data on Egyptian hypertensive
patients, this study was planned to be conducted on large number of
patients to show the results in real-life setting.
Methods: Study design Multicenter, observational, Post Marketing
Surveillance (PMS) study. The total duration of treatment with SPC
of amlodipine/valsartan 5/160 and 10/160 in this study was 12 weeks.
In accordance with the deﬁnition of non-intervention studies, therapy
was prescribed in terms of the marketing authorization. The assign-
ment of patient to therapy was decided based on clinical evaluation
and was separated from the decision to include the patient in the study.
The dose of SPC of amlodipine/valsartan prescribed by the treating
physician was recorded at the initial visit. Concomitant medications,
including antihypertensive medications were allowed in the study.
Patients were observed over a 3-months period. Patients could discon-
tinue participation in the study for any reason. In the event of prema-
ture discontinuation, the investigators were requested to document the
reason for discontinuation
Patients: Males or females, >18 years of age, with hypertension (SBP/
DBP >140/90 mmHg), for whom an antihypertensive therapy with the
SPC of Valsartan 160 mg and Amlodipine 5 or 10 mg once daily is clin-
ically recommended, were included in the study. All patients were
asked to provide written informed consent before participating in the
study. Women who were pregnant, intending to become pregnant or
breastfeeding, patients with severe medical condition(s) that in the view
of the investigator prohibits participation in the study e.g. severe renal
or hepatic impairment and hypersensitivity to valsartan, amlodipine or
any of the components in the formulation were excluded from the
study. Independent ethical committee approval was obtained before
the study initiation as per the local regulations.
Study procedures: At baseline, patients were assessed for demographic
details, history, concomitant diseases, previous antihypertensive medi-
cations, blood pressure, and heart rate. Suitable dose of amlodipine/
valsartan SPC was studied. The dose was adjusted during the follow
up visits by the treating physician. Patients were monitored closely
for change in SBP/DBP and heart rate during follow up visits for 12
weeks. Safety and tolerability assessments included the recording of
adverse events (AEs) and serious adverse events (SAEs) throughout
the study, irrespective to suspected relation to study medication. No
additional diagnostic or monitoring procedures were performed. Pri-
mary end point was comparison of systolic and diastolic blood pres-
sure and heart rate at study start and after 12 weeks of therapy with
amlodipine/valsartan 5/160 mg or amlodipine/valsartan 10/160 mg.
Secondary endpoint was evaluation of the blood pressure lowering
eﬀect in terms of response rates and evaluation of AEs and SAEs.
Investigators entered the required patients’ data in the Case Report
Form (CRF). It was entered anonymously into the study database, val-
idated and analyzed.
Statistical analysis: A total of 2489 patients were enrolled and 2357
completed the study (Intent To Treat population). Analysis of
results included descriptive statistics of the demographic data as well
as eﬃcacy and safety data. To determine statistical signiﬁcance of
eﬃcacy and safety data, chi square test has been used to compare
categorical results, while t-test has been used to compare two means
and ANOVA for comparison of more than 2 means. Statistical sig-
niﬁcance limit was taken to be 0.05. Patients were analyzed as one
group and were also divided into clinically relevant groups. In post-
hoc analysis, patients were divided according to the prescribed dos-
age into 4 groups (up and down-titration were the decision of the
treating physician); Group 1: Started amlodipine/valsartan 5/160 in
V1 and maintained on amlodipine/valsartan 5/160 to V4 (33% of pa-
tients; n= 789), Group 2: Started amlodipine/valsartan 5/160 in V1
and increased to amlodipine/valsartan 10/160 in V2 or V3 (23% of pa-
tients; n= 535), Group 3: Started amlodipine/valsartan 10/160 at V1
and maintained on amlodipine/valsartan 10/160 to V4 (27% of
patients; n= 630), Group 4: Started amlodipine/valsartan 10/160 at
V1 and decreased to amlodipine/valsartan 5/160 to V4 (15% of pa-
tients; n= 344).
Results: Total of 2489 patients were enrolled in the study 2357 pa-
tients completed the four visits of the study and were evaluable for eﬃ-
cacy analysis. The baseline demographic details are shown in Table 1.
51.4% (n= 1212) of patients were on other concomitant medica-
tions. The leading concomitant diseases for which concomitant medi-
cations were indicated were: Diabetes (27.3%), Hypertension (13%),
Hypercholesterolemia (11.8%), Ischemic Heart Diseases (11.7%),
Table 1
Demographic and baseline characteristics (n= 2357).
Age (Y) Mean 54.06
SD 9.68
Age group-n <40 years 200
41–50 years 672
51–60 years 933
>60 years 539
Weight (Kg) Mean 87.2
SD 13.8
Smoker-n Smoker 683
Non-smoker 1660
Hypertension duration (Y) Mean 6.94
SD 5.62
Diabetes – % Diabetics 25%
Non-Diabetics 75%
Table 2
Antihypertensive therapy taken before switching to study medication.
Antihypertensive medications (n,%) Beta blockers 954 27.3%
ACE Inhibitors 861 24.7%
Diuretics 783 22.4%
Calcium channel blockers 499 14.3%
ARBs 358 10.3%
Others 34 1.0%
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Dyslipidemia (7.6%) and Hyperuricemia (6.1%). Eighty ﬁve percent of
the patients were on antihypertensive treatment before the start of the
study. Table 2 summarizes these antihypertensive medications.
Antihypertensive eﬃcacy: The study results demonstrate that overall
mean systolic blood pressure at baseline (n= 2357) was 171.5 mmHg,
it was reduced to 144.1 mmHg after 4 weeks, 135.8 mmHg after 8
weeks and 131.7 mmHg after 12 weeks with a very highly signiﬁcant
overall mean reduction of 39.8 mmHg; p ¼< 0:0001. Mean diastolic
blood pressure at baseline was 103.4 mmHg, it was reduced to
88.8 mmHg after 4 weeks, 84.1 after 8 weeks and 82 mmHg after 12
weeks with a very highly signiﬁcant overall mean reduction of
21.4 mmHg; p ¼< 0:001 (see Fig. 1). In post-hoc analysis, signiﬁcant
reduction in BP after 12 weeks treatment with amlodipine/valsartan
5/160 and/or 10/160 in the four groups of patients. In Group 1
(n= 789); mean reduction in SBP 34.6 mmHg and DBP
19.1 mmHg (p < 0.0001), in Group 2 (n= 535); mean reduction in
SBP 36.3 mmHg and DBP 19.9 mmHg (p < 0.0001), in Group 3
(n= 630); mean reduction in SBP 47.1 mmHg and DBP
24.3 mmHg (p < 0.0001), in Group 4 (n= 344); mean reduction in
SBP 44.9 mmHg and DBP 23.7 mmHg (p < 0.0001) after 12 weeks
of treatment Fig. 2.
Blood pressure response rates: BP control rates were also evaluated in
our study Fig. 3. A total of 87.9%of patients had their SBP orDBP con-
trolled (<140 or<90 mmHg; respectively). Strict BP control (BP<140/
90 mmHg) was achieved in 70.3% of patients. Percentage of patients
reachedSBPgoal (<140 mmHg)was 73.9%andDBPgoal (<90 mmHg)
was 84.3%. Percentage of patients reached the BP goal<130/80 mmHg
was 31%.
Heart rate: There is a statistically signiﬁcant decrease in heart rate
from baseline to end of the study. Heart rate dropped from 82 bpm
at baseline to 78.4 bpm after 12 weeks of treatment (p<0.001).
Blood pressure reduction by patients’ co morbidities: When clinically
relevant groups were analyzed, highly signiﬁcant BP reduction was
achieved Fig. 4. In patients with hypercholesterolemia (Group A);
Baseline SBP/DBP was 173.1/104.1 mmHg and reached 131.7/
82.1 mmHg after 3 months (41.4/22 mmHg; p= 0.00001). In pa-
tients with coronary heart diseases (Group B); Baseline SBP/DBP
was 175.8/105 mmHg and reached 132.8/82.3 mmHg after 3 months
(43/22.7 mmHg; p= 0.00001). In patients with Diabetes (Group
C); baseline SBP/DBP was 173.2/103.5 mmHg and reached 132.1/
81.9 mmHg after 3 months (41.1/21.6 mmHg; p= 0.00001). In
patients with hyperuricemia (Group D); baseline SBP/DBP was
173.3/104.7 mmHg and reached 131.1/82.1 mmHg after 3 months
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Fig. 2. Blood pressure control rates.
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Fig. 1. Mean SBP and DBP during treatment with SPC of amlodipine/valsartan.
SBP = systolic blood pressure; DBP = diastolic blood pressure, n ¼ 2375.
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Fig. 3. Mean BP reduction in the 4 patients’ groups after 12 weeks treatment with single-pill combination amlodipine/valsartan 5/160 and/or 10/160; SBP = systolic blood pressure;
DBP = diastolic blood pressure, n= 2375.
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(42.2/22.6 mmHg; p= 0.00001). In patients with Heart Failure
(Group E); baseline SBP/DBP was 175.9/104.6 mmHg and reached
130.7/81.8 mmHg after 3 months (45.2/22.8 mmHg; p= 0.00001).
In patients with respiratory diseases (Group F); baseline SBP/DBP
was 174/103.7 mmHg and reached 134.1/82.8 mmHg after 3 months
(39.9/20.9 mmHg; p= 0.00001).
Safety and tolerability: Combination amlodipine/valsartan was well
tolerated in this study Table 3. A total of 126 AEs were reported in
104 (4.4%) patients; 75 AEs were suspected by the treating physician
to be related to study medication, 48 AEs were considered not related
and, for 3 AEs, the physician’s evaluation was not provided. Of the
reported adverse events, 77.6% were mild, 20.8% were moderate and
1.6% were severe.
Analysis of intensity of edema showed that at baseline, 77% had
mild edema, 21% had moderate edema, and 2% had severe edema.
After 12 weeks of treatment, 89% of edema cases were considered
mild, 11 % were moderate, and 1 % were severe. SAEs were reported
in 2 cases that died during the study. Deaths were due to complications
resulting from duodenal ulcer and renal failure. Causes of death were
assessed by the investigator as not related to study medication. Twenty
One patients had prematurely discontinued the Study medication. Rea-
sons for premature discontinuation included lost follow up (9), adverse
events (4), subjects no longer requiring the study drug (3), consent
withdrawal (3) and death (2).
Investigator’s overall assessment of tolerability and compliance: Physi-
cians rated tolerability in 75.6% of patients to be Excellent, 21.2%
as Very Good, 3.2% as Good and 0% as poor. They rated patients’
compliance in 77.4% of patients to be Excellent, 19.2% as Very Good,
2.8% as Good and 0.5% as poor.
Patient’s overall assessment of tolerability and compliance: Patients
rated tolerability to Amlodipine/valsartan combination was rated
Excellent in 70.7% of patients, 22.6% as Very Good, 5.3% as Good
and 0.1% as poor. They rated compliance to this medication as
Excellent in 72.5%, 21.4% as Very Good, 4.4% as Good and 0.6%
as poor.
Discussion: In this a post marketing observational study, designed to
represent real-life setting, SPC of amlodipine/valsartan was shown to
signiﬁcantly reduce the BP. Analyses for patients with concomitant
medical conditions (e.g.: hypercholesterolemia, Ischemic heart dis-
eases, diabetes, and heart failure) demonstrated the antihypertensive
eﬃcacy of this combination among these populations.
The National Institute for Health and Clinical Excellence (NICE)
Guideline Development Group stated that most of hypertensive
patients require more than one drug to reach the BP goal. For hyper-
tensive patients whose blood pressure is not controlled by A (ACEi or
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Fig. 4. Mean BP response in the 6 patients’ groups before and after 12 weeks treatment with single-pill combination amlodipine/valsartan 5/160 and/or 10/160; SBP = systolic blood
pressure; DBP = diastolic blood pressure.
Table 3
Reported adverse events:
Adverse event n, Patient (%)
Edema 84 (3.6%)
Headache 16 (0.7%)
GIT disorder 8 (0.3%)
Elevated liver enzymes 5 (0.2%)
Flushing 4 (0.2%)
Postural hypotension 4 (0.2%)
Pharyngitis 3 (0.1%)
Fatigue 1 (0%)
Diabetes 1 (0%)
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ARB) in young adults (55 years) and C (CCBs) or D (Diuretics) in
older patients (>55 years) which is step 1 treatment. If failed, step 2
should be considered as a combination of A + C or A + D.6
Combination of ARB/CCB provides enhanced blood pressure low-
ering eﬃcacy compared with the eﬀect of ARBs or CCBs as monother-
apies and may promote a counter-regulatory response. Activation of
sympathetic nervous system by CCB induced vasodilation is dimin-
ished by blockade of RAAS with ARB. The antihypertensive eﬀect
of the ARB/CCB combination may not be only additive but also
synergetic.7
The results of our study supported the results of previously con-
ducted amlodipine/valsartan randomized controlled clinical studies.
Dose dependent BP lowering by amlodipine/valsartan combination
was demonstrated by Philipp et al8 and further analysis performed
by Smith et al.9 conﬁrmed that the degree of BP lowering corresponded
to the initial hypertension stage. Poldermans et al study provided
evidence that in patients with mean BP 180/110 mmHg amlodipine/
valsartan combination provided a SBP reduction of 43.0 mmHg
and it was numerically greater than that provided by lisinopril/hydro-
chlorothiazide combination in this subgroup of patients
(31.2 mmHg).10
In our study, a reduction of the SBP of 39.8 mmHg and
21.4 mmHg in DBP conﬁrms that amlodipine/valsartan combination
is eﬀective in lowering BP. This is consistent with results of large post
marketing study included 2785 hypertension patients demonstrated
that amlodipine/valsartan combination signiﬁcantly reduces BP in
patients with arterial hypertension. The BP lowering eﬀect was dose
dependent and also corresponded to the baseline level of BP eleva-
tion.11 In this observational study, single-pill combination amlodip-
ine/valsartan was shown to signiﬁcantly reduce BP in a manner that
was dose dependent and corresponded to the severity of baseline BP
conﬁrming the previous evidences.
Another observational study has reported the same eﬃcacy proﬁle
with overall mean BP reduction after a 12-week course of SPC of
amlodipine/valsartan as 36.3/18.9 mmHg (mean BP of 165.0/
99.3 mmHg at week 1 vs. 128.7/80.4 mmHg at week 12).12
Another interesting ﬁnding in our study is that there was a signif-
icant decrease in heart rate from baseline to end of the study, providing
evidence that there was no unfavorable eﬀect of amlodipine in combi-
nation with valsartan on heart rate as one could expect.
Peripheral edema is a well-known dose-dependent and dose-limit-
ing side eﬀect of treatment with CCBs, recognized as a consequence
of imbalances involving hydrostatic and oncotic pressure gradients
and vascular permeability.13 A recent meta-analysis of CCB-based
antihypertensive therapy found that the incidence of, and treatment
withdrawal rate for, this toxicity increased with the duration of ther-
apy, with 24% of patients reported peripheral edema and 5% of
patients with peripheral edema-related discontinuation after 6
months.14 Administering a CCB in conjunction with a Renin Angio-
tensin Aldosterone System (RAAS) blocker is among the proposed
means for mitigating both the incidence and severity of CCB-related
peripheral edema15,16 demonstrating a 38% lower incidence of
peripheral edema versus CCB monotherapy (relative risk, 0.62;
P < 0.00001) as well as a 62% reduction in the risk of peripheral ede-
ma-related withdrawal (relative risk, 0.38; P < 0.01). In a real life set-
ting study, a 8.5% incidence of peripheral edema at study end was
reported as well.12
In the current study, Incidence of edema had not increased, on the
other hand; the severity of edema was decreased at the end of the
study. The reduction in severity of peripheral edema over time reﬂects
the complementary mechanism of action of the CCB and ARB classes.
In the current study also, clinically relevant groups were analyzed
in a post-hoc analysis, a highly signiﬁcant BP reduction with amlodip-
ine/valsartan single pill combination was achieved in patients with
hypercholesterolemia with 41.4/22 mmHg reduction from baseline,
patients with coronary heart diseases 43/22.7 mmHg from baseline,
in patients with diabetes 41.1/21.6 mmHg reduction from baseline
and in patients with heart failure 45.2/22.8 mmHg reduction from
baseline with good safety and tolerability proﬁle.
Compliance is deﬁned by the World Health Organization (WHO)
as “the extent to which a person’s behavior – taking medication, fol-
lowing a diet, and/or executing lifestyle changes, corresponds with
agreed recommendations from a health care provider”.17 In relation
to the management of hypertension, poor patient compliance is one
of the most common causes of patient’s failure to reach BP control,
on the other hand; There was a positive association between BP con-
trol and compliance, about 75% of compliant patients achieve BP
<140/90 mmHg, compared with only 10% of non-compliant
patients.18 In the Canadian Hypertension Education Program (CHEP)
2013, adherence and non-adherence to healthy lifestyle and pharmaco-
therapy is an important cause of poor blood pressure control. Patient
adherence to lifestyle modiﬁcations and pharmacotherapy should be
assessed on each visit and interventions to improve adherence should
be a part of routine clinical practice. Strategies to improve patient
adherence are: (i) Simplifying medication regimen to once-daily dos-
ing; (ii) Replacing multiple pill antihypertensive combinations with sin-
gle pill combinations.19 Costa et al., mentioned that, when considering
together monotherapy and ﬁxed-dose combinations, ARBs showed the
highest persistence rate among all antihypertensive medications;
among ARBs, valsartan has the lowest risk of non-persistence.20 These
ﬁndings and recommendations are matched with and may explain high
patients’ satisfaction results with valsartan/amlodipine ﬁxed dose com-
bination in our study.
Also, As regards investigators assessment of amlodipine/valsartan
SPC, 78.1% assessed it as excellent regarding eﬃcacy 75.6% regarding
tolerability. 70.7% of patients rated tolerability to Amlodipine/valsar-
tan combination as Excellent.
Limitations: This study was non-randomized, uncontrolled, and
observational in nature. Limitations of observational studies in general
include the potential for observational bias due to lack of blinding and
the absence of standardized data collection. The real-life setting of the
current study does not allow the authors to make deﬁnitive conclusions
concerning comparative eﬃcacy and safety of the studied combination.
On the other hand, the observational design of this study made possible
the acquisition of a large amount of data in a broad population of hyper-
tensive patients with a variety of clinical conditions and comorbid dis-
eases, which makes the results more relevant to real clinical practice.
Conclusion: In a large cohort of uncontrolled hypertensive patients,
SPC of amlodipine/valsartan provided eﬀective blood pressure reduc-
tion and control with good tolerability. This data provides beneﬁcial
evidence of this combination in Egyptian hypertensive patients.
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